SNY won't admit it but they had a shortage for all syringe doses especially the HD syringes because they were anticipating a TEVA entry that never came into fruition.. I.e. they bought less raw material (heparin); thus they have less available branded drug. They redirected all they had for their hospital contracts still in place to remain in a favorable status. Mostly HD was redirected, because they already had a shortage of low dose before March.
SNY effectively has given MNTA free reign in retail and its showing. They only way SNY can continue to pull in revenue for Lovenox is maintaining their GPO sole source contracts. This means all available drug will be sold to GPO.
Market Data 
Markets 
AI
